Trial · NCT07245680
COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities
NCT07245680, Phase 3, Recruiting, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities. Trials, record NCT07245680. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07245680
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities
- NCT number
- NCT07245680
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 186 participants, estimated
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Pulmonary Arterial Hypertension (PAH), Comorbidities, Cardiovascular Disease (CVD)
- Interventions
- Tadalafil, Ambrisentan, Placebo (Ambrisentan-matching)
- First posted
- 2025-11-24
- Last updated
- 2026-05-13
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mesurement of the risk profile according to the non-invasive 4-risk strata method | Week 24 | Proportion of patients with PAH and with at least two cardiovascular comorbidities who achieve after 24 week a low- or an intermediate-low risk profile according to the non-invasive 4-risk strata method as proposed by the 2022 european pulmonary hypertension guidelines. |
| Secondary | Pulmonary vascular resistance | week 24 | Change from baseline to Week 24 in pulmonary vascular resistance, assessed by right heart catheterization and expressed in Wood units (WU). |
| Secondary | BNP or NT-proBNP | Week 24 | Percent change from baseline to week 24 in BNP or NT-proBNP |
| Secondary | 6-Minute Walk Distance (6-MWD) | Week 24 | Change from baseline to week 24 in 6-MWD |
| Secondary | WHO/NYHA Functional class | Week 24 | Proportion of participants who improve in WHO/NYHA FC at the end of the DBPC Treatment period |
| Secondary | TAPSE/systolic pulmonary artery pressure (SPAP) ratio | Week 24 | Change from baseline to week 24 in the TAPSE/systolic pulmonary artery pressure (SPAP) ratio |
| Secondary | Death or Nonfatal Clinical Worsening | Week 24 | Rate of Death or Nonfatal Clinical Worsening defined by hospitalisation for PAH worsening or disease progression defined by worsening of functional class and decrease in 6-min walk distance of more than 15% from baseline, or need for additional specific therapy or lung transplantation |
| Secondary | emPHasis-10 score | Week 24 | Change from baseline to week 24 in the emPHasis-10 score |
| Secondary | EuroQoL-5 dimensions scale 5 levels (EQ-5D-5L) | Week 24 | Change from baseline to week 24 EuroQoL-5 dimensions scale 5 levels (EQ-5D-5L) |
| Secondary | Death | Week 24 | All causes of death |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07245680
GET https://conductscience.org/api/trials/v1/NCT07245680/registered